Cargando…
Endocan in Acute Leukemia: Current Knowledge and Future Perspectives
Endocan is a soluble dermatan sulfate proteoglycan expressed by endothelial cells and detected in serum/plasma. Its expression is increased in tumors/tumor vessels in several human malignancies, and high expression (high serum/plasma levels or tumor levels) has an adverse prognostic impact in severa...
Autores principales: | Reikvam, Håkon, Hatfield, Kimberley Joanne, Wendelbo, Øystein, Lindås, Roald, Lassalle, Philippe, Bruserud, Øystein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027427/ https://www.ncbi.nlm.nih.gov/pubmed/35454082 http://dx.doi.org/10.3390/biom12040492 |
Ejemplares similares
-
Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis
por: Mosevoll, Knut Anders, et al.
Publicado: (2014) -
Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation
por: Lindås, Roald, et al.
Publicado: (2014) -
Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers
por: Reikvam, Håkon, et al.
Publicado: (2018) -
Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls
release of angioregulators from primary human acute myeloid leukemia cells and their
neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2017) -
Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2013)